Johannes Czernin, MD, and Jérémie Calais, MD, MSc, both with the University of California, Los Angeles, explain how supply has become a large issue for Lutetium-177–PSMA-617, the consequences of this shortage, and strategies to overcoming the issue.
The Lutetium-177–PSMA-617 supply problem will be solved by competition, they contend. Additionally, they comment on other factors contributing to the supply issue that competition and different manufacturing sites will not fix.
They also highlight some of the other compounds that will add to the market in 2024 and beyond.
As of April 21, 2023, Novartis has been given FDA approval to start producing Lutetium-177–PSMA-617 at its facility in Millburn, New Jersey.